Abstract:Urease, a nickel-dependent enzyme found in various life forms, catalyzes urea breakdown, concluding nitrogen metabolism by generating ammonia and carbamate. This process causes a rise in pH, supports the survival of pathogens, and can lead to infections such as gastric disorders like ulcers and cancer in humans. Helicobacter pylori employs urease for survival in the acidic environment of the stomach and in protein synthesis. To treat such infections and inhibit the growth of pathogens, it is mandatory to obstruct urease activity; therefore, derivatives of 1-(3-nitropyridin-2-yl)piperazine were synthesized ( 5a-o ; 7a-k ). All these newly synthesized compounds were investigated for urease inhibition by in vitro inhibition assays. The results showed that 5b and 7e are the most active inhibitors, having IC 50 values of 2.0 ± 0.73 and 2.24 ± 1.63 μM, respectively. These IC 50 values are lower than the IC 50 value of the standard thiourea, which was 23.2 ± 11.0 μM. The hemolysis potential of 5b, 5c, 5i, 7e, and 7h was also determined; 7e and 7h exhibited good biocompatibility in human blood cells. Through in silico analysis, it was shown that both these potent inhibitors develop favorable interactions with the active site of urease, having binding energies of −8.0 ( 5b ) and −8.1 ( 7e ) kcal/mol. The binding energy of thiourea was −2.8 kcal/mol. Moreover, 5b and 7e have high gastrointestinal permeability as predicted via computational analysis. On the other hand, the IC 50 value and binding energy of precursor compound 3 was 3.90 ± 1.91 μM and −6.1 kcal/mol, respectively. Consequently, 5b and 7e can serve as important inhibitors of urease.

Synthesis and Evaluation of N-analogs of 1,2-Diarylethane As Helicobacter Pylori Urease Inhibitors.

3-Arylpropionylhydroxamic Acid Derivatives As Helicobacter Pylori Urease Inhibitors: Synthesis, Molecular Docking and Biological Evaluation

Arylamino Containing Hydroxamic Acids As Potent Urease Inhibitors for the Treatment of Helicobacter Pylori Infection.

Synthesis, Molecular Docking and Kinetic Properties of Β-Hydroxy-β-phenylpropionyl-hydroxamic Acids As Helicobacter Pylori Urease Inhibitors

The Synthesis, Structure and Activity Evaluation of Pyrogallol and Catechol Derivatives As Helicobacter Pylori Urease Inhibitors

Amines and oximes derived from deoxybenzoins as Helicobacter pylori urease inhibitors.

Synthesis and Biological Evaluation of Triazolones/oxadiazolones As Novel Urease Inhibitors

The Synthesis and Evaluation of Phenoxyacylhydroxamic Acids As Potential Agents for Helicobacter Pylori Infections

Synthesis and Biological Evaluation of Dithiobisacetamides as Novel Urease Inhibitors

Synthesis, molecular docking and biological evaluation of metronidazole derivatives as potent Helicobacter pylori urease inhibitors.

Design and synthesis of novel anti-urease imidazothiazole derivatives with promising antibacterial activity against Helicobacter pylori

Developing potential Helicobacter pylori urease inhibitors from novel oxoindoline derivatives: Synthesis, biological evaluation and in silico study.

Pyridylpiperazine-based carbodithioates as urease inhibitors: synthesis and biological evaluation

Design and discovery of urease and Helicobacter pylori inhibitors based on benzofuran/benzothiophene-sulfonate and sulfamate scaffolds for the treatment of ureolytic bacterial infections

Molecular design of hydroxamic acid-based derivatives as urease inhibitors of Helicobacter pylori

Synthesis and biological evaluation of pyridylpiperazine hybrid derivatives as urease inhibitors

The synthesis, structure and activity evaluation of secnidazole derivatives as helicobacter pylori urease inhibitors

Synthesis, molecular docking and biological evaluation of 3-arylfuran-2(5H)-ones as anti-gastric ulcer agent

N -monoarylacetothioureas as potent urease inhibitors: synthesis, SAR, and biological evaluation.

Identification of (N-aryl-N-arylsulfonyl)aminoacetohydroxamic acids as novel urease inhibitors and the mechanism exploration

Synthesis, Evaluation and Mechanism Exploration of 2-(N-(3-nitrophenyl)-n-phenylsulfonyl)aminoacetohydroxamic Acids As Novel Urease Inhibitors.